Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17302255 | 0.88 | PRMT5 (0.41) | PRMT5WDR77 | |
| SCHEMBL15381065 | 0.88 | NNMT (0.35) | — | |
| SCHEMBL23120133 | 0.86 | PRMT5 (0.42) | PRMT5WDR77 | |
| SCHEMBL30941081 | 0.86 | PRMT5 (0.42) | PRMT5WDR77 | |
| SCHEMBL17302276 | 0.84 | PRMT5 (0.34) | PRMT5WDR77 | |
| SCHEMBL17936459 | 0.84 | PRMT5 (0.34) | PRMT5WDR77 | |
| SCHEMBL23120330 | 0.83 | PRMT5 (0.32) | PRMT5WDR77 | |
| SCHEMBL23120331 | 0.81 | ACACB (0.33) | PRMT5WDR77 | |
| SCHEMBL17549887 | 0.80 | ADK (0.30) | — | |
| SCHEMBL15381061 | 0.77 | AHCY (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458165-B2 | DOT1L inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458165-B2 | DOT1L inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458165-B2 | DOT1L inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9394310-B2 | Carbocycle-substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394310-B2 | Carbocycle-substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160060269-A1 | DOT1L Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160060269-A1 | DOT1L Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160060269-A1 | DOT1L Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. | 2016-03-03 | — | — | US | disclosed |
| EP-2646441-B1 | CARBOCYCLE-SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | EPIZYME INC (US) | 2015-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060269-A1 | DOT1L Inhibitors | DOT1L, MAP1LC3B, MAP1LC3A | PRMT5 608/4885WDR77 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.